Bombora and Simpli.fi Received Dick Reed Award for Channel Advancements and Innovation by Just Global
NEW YORK--(BUSINESS WIRE)-- B ombora, a B2B data provider, has been awarded a Dick Reed Award for Channel Advancements & Innovation. This honor, also awarded to Simpli.fi, recognizes Bombora and Simpli.fi's first-to-market contextual targeting solution.
The Dick Reed Awards honor pioneers and innovators who are revolutionizing the B2B marketing landscape. Each year, the awards highlight leaders who demonstrate visionary thinking, strong partnerships, and impactful solutions that push the boundaries of what's possible in B2B marketing.
Bombora and Simpli.fi's first-to-market contextual targeting solution combines Bombora's patented Company Surge® Intent data with Simpli.fi's granular native targeting platform to allow B2B marketers to reach their target audiences in relevant ways, at the scale they need. This solution, derived from Bombora's one-of-a-kind Data Cooperative, gives advertisers access to more than 70 topic-oriented audience segments, including highly relevant topics like 'machine learning and artificial intelligence' and 'cryptocurrency'.
'Receiving the Dick Reed Award is further validation of our commitment to empower B2B marketing through data, insights, and strategic collaborations," said Mark Connon, CEO of Bombora. 'Our integration with Simpli.fi showcases how Bombora's B2B Intent data solution can unlock new opportunities and elevate results for brands and agencies to engage with the right audiences at the right time, across the right channels.'
About Bombora
The true B2B data pioneer, Bombora connects the B2B ecosystem in a one-of-a-kind Data Co-op of leading publishers, brand websites, and premium data providers. Leveraging advanced AI models, Bombora creates a holistic view of company research behavior enabling brands, agencies, and publishers to identify, understand, and reach their prospects and customers. Bombora provides a range of leading Intent, Identity, B2B Audiences and Campaign Measurement solutions, and makes them accessible within almost every B2B MarTech, RevTech, SalesTech and AdTech solution.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Share 'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.' The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1 'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.' ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery. 'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance. In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis. AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide. Indications In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of: hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Important Safety Information Reduced Serum Vitamin A Levels and Recommended Supplementation Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness). Adverse Reactions Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. For additional information about vutrisiran, please see the full Summary of Product Characteristics. About AMVUTTRA ® (vutrisiran) AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers. About ATTR Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Associated Press
35 minutes ago
- Associated Press
eClerx Expands Global Outreach with New Delivery Center in Cairo, Egypt
NEW YORK--(BUSINESS WIRE)--Jun 9, 2025-- eClerx Services Ltd ( a leading productized services provider, today announced the launch of a new delivery center in Cairo, Egypt. This strategic expansion strengthens eClerx's global operations and reinforces its commitment to driving innovation and harnessing top-tier talent in high-growth markets. The Cairo center will serve as a major expansion in technical support operations for one of eClerx's largest telecom clients. Nestled between Africa, Europe, and Asia, this center enables eClerx to serve several of its largest clients in the US and European markets, providing enhanced multilingual support. 'The opening of our Cairo delivery center marks the second new country opening for eClerx this year in line with our mission to deliver seamless, tech-enabled customer care experiences to our clients,' said Kapil Jain, CEO of eClerx. For 25 years, eClerx's deep domain expertise and innovative technology solutions have provided clients access to enhanced customer journeys, improved CSAT, and offered valuable insights that help them remain competitive in their industry. The addition of this center in Egypt will not only enable eClerx to offer these services to more clients worldwide but also allow the company to leverage the wealth of talent and expertise present locally. 'Cairo's rich talent pool, coupled with its thriving tech ecosystem and strategic geographical location, makes it an ideal region to invest in,' said Michael Hutchison, Head of Customer Operations at eClerx. 'We are excited to be in an area so robust with innovation and resilience, and we look forward to creating valuable opportunities for local talent while continuing to drive transformative outcomes for our global partners.' This new delivery center underscores eClerx's commitment to deliver excellence, foster innovation, and strengthen partnerships with both its clients and the local community. For more information about eClerx's services and global delivery centers, please visit About eClerx eClerx provides business process management, automation, and analytics services to a number of Fortune 2000 enterprises, including some of the world's leading financial services, communications, retail, fashion, media & entertainment, manufacturing, travel & leisure, and technology companies. Incorporated in 2000, eClerx is today traded on both the Bombay and National Stock Exchanges of India. The firm employs more than 19,000 people across Australia, Canada, France, Germany, India, Italy, Netherlands, Peru, Philippines, Singapore, Thailand, the UK, and the USA. View source version on CONTACT: Media contact Prathibha Das Head-Brand & Corporate Marketing [email protected] KEYWORD: NEW YORK AFRICA EGYPT UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PROFESSIONAL SERVICES BUSINESS DATA ANALYTICS SMALL BUSINESS FINANCE CONSULTING ACCOUNTING SOURCE: eClerx Services Ltd Copyright Business Wire 2025. PUB: 06/09/2025 05:17 AM/DISC: 06/09/2025 05:15 AM
Entrepreneur
an hour ago
- Entrepreneur
First Citizens India Expands Operations with New Bengaluru Facility
The GCC's mandate covers the delivery of enterprise-grade solutions across core functions critical to the bank's infrastructure and customer engagement strategies You're reading Entrepreneur India, an international franchise of Entrepreneur Media. First Citizens India, the Global Capability Centre (GCC) of U.S.-based First Citizens BancShares, Inc., has opened a new office in Bengaluru, signaling a deepened commitment to India as a strategic operations hub. The announcement was made through a press release issued by the company. The Bengaluru facility features a collaborative and digitally enabled environment designed to support cross-functional teams and foster innovation. The move comes amid the bank's broader push to enhance digital transformation and operational resilience in response to evolving client expectations and market demands. Jeff Ward, chief strategy officer at First Citizens Bank, who is currently in India to mark the inauguration of the new site, noted the importance of the region in the bank's broader vision. "Our decision to expand our footprint in the established hub of Bengaluru allows us to strategically leverage the country's vast talent pool and directly support the long-term commitment to our enterprise vision," he said. The expansion reflects the growing role of India in supporting First Citizens Bank's global operations, particularly in areas such as technology, cybersecurity, finance, risk management, and enterprise operations. First Citizens India has played an increasingly vital role in this transformation journey, integrating the bank's relationship-driven service model into a high-performance global operations framework. The GCC's mandate covers the delivery of enterprise-grade solutions across core functions critical to the bank's infrastructure and customer engagement strategies. Satya Prakash Ranjan, country head and head of technology at First Citizens India, emphasized the dual role of the new office as a center for delivery and talent development. "As we continue to modernise and scale the bank's technology platforms, this facility and our local team give us the flexibility and environment needed to deliver enterprise-grade solutions across a variety of functions," he said. "We are hiring and welcoming colleagues to help us deliver business solutions based on the bank's shared values."
